PDCD1 and melanoma: The few studies to date have only incorporated pembrolizumab, nivolumab (anti‐PD‐1) and ipilimumab (CTLA‐4) therapy, and other ICIs or combination therapies with SOC therapies have only been described for feasibility studies in melanoma.87